Sleep Number (SNBR) Q3 2024 Earnings Transcript

Sleep Number reported Q3 net sales of $427 million, down 10% year over year and 5 percentage points below expectations, while adjusted EBITDA rose 11% to $28 million on a 340 bps gross margin expansion to 60.8%. Management cut full-year adjusted EBITDA guidance to $115 million-$125 million from $125 million-$145 million and reduced free cash flow guidance to $10 million-$20 million, citing continued weak bedding demand and slightly softer Synchrony approval/usage. The company also announced CEO Shelly Ibach will retire by the 2025 annual meeting, with a transition planned through the end of 2025.

Analysis

The key takeaway is not the quarter itself, but that management is effectively telling you the earnings power floor has reset lower while the balance sheet has only modestly improved. Cost actions are doing the heavy lifting now; that helps near-term EBITDA and covenant math, but it also makes the model more levered to any incremental demand disappointment because there is less “easy” expense left to cut. In other words, the market should treat margin expansion as largely self-help-driven, not a signal of demand inflection.

The leadership transition adds another layer of uncertainty because it lands right as the company is trying to preserve strategic optionality. A new CEO will likely inherit a business where the obvious next move is not growth investment but portfolio pruning, channel discipline, and further working-capital management. That tends to suppress valuation multiples in the near term because investors lose confidence in the timing of a real top-line reacceleration and instead focus on whether the business can stay comfortably inside covenants through the first-half refinancing window.

The more interesting second-order effect is on competition and suppliers: if Sleep Number keeps leaning into high-margin innovation and selective media, smaller mattress players with weaker direct channels and less flexibility in promo cadence may feel more pressure on traffic and inventory turns. But the company’s own product mix is still being pulled by promotional weekends, which suggests the category is behaving like a liquidity-sensitive discretionary purchase rather than a branded innovation category. That is bearish for anyone underwriting a clean recovery in 2025.

Contrarian view: the setup is not a collapse story, it is a cash-preservation story with a modestly improved downside cushion. If demand merely stabilizes, the combination of gross margin discipline, lower capex, and store rationalization could create enough free cash flow to de-risk the equity more than the headline sales decline implies. The problem is timing: the next catalyst is likely not better demand, but confirmation that Q1 covenant math still holds under a weak backdrop.

Key Decisions for Investors

• Maintain/expand a tactical short SNBR position into the next 4-8 weeks; the stock should stay range-bound or leak lower until the market gets evidence of post-holiday demand stabilization. Risk: a stronger-than-expected Q1 margin beat could squeeze the short; use a tight stop above any sustained breakout tied to covenant relief headlines.
• Consider a bearish call spread on SNBR (e.g., 3-6 month tenor) to express downside with defined risk. Best risk/reward if the market re-rates the name lower on succession uncertainty and continued demand deterioration, while the options cap loss if the company continues to out-save estimates.
• Pair trade: long better-quality discretionary home-related names with stronger secular demand and balance sheets, short SNBR. The relative trade benefits if consumer spending remains selective and financing-sensitive, because SNBR is more exposed to delayed purchases and promo concentration than peers.
• If holding SNBR common, use strength to sell into any relief rally rather than averaging down. The stock needs either a clear 2025 demand inflection or a more meaningful deleveraging step before multiple expansion is justified.